Skip to main content

Table 2 Demographic and Clinical Characteristics

From: A Cost-Consequences analysis of the effect of Pregabalin in the treatment of peripheral Neuropathic Pain in routine medical practice in Primary Care settings

Characteristic Non-PGB
(N = 157)
PGB monotherapy
(N = 577)
PGB add-on
(N = 575)
P
Gender (female), n (%) 87 (55.3) 349 (60.4) 332 (57.8) 0.4874
Age, mean (SD) 60.4 (12.4) 58.6 (12.5) 59.7 (13.0) 0.1486
Body Mass Index (Kg/m2) 26.9 (3,5) 27.3 (3,8) 27.3 (3,9) 0.4673
Civil status (married or with couple), n (%) 108 (69.0%) 383 (66.4%) 389 (67.6%) 0.6041
Working status, n (%)     
   Active 51 (32.5) 200 (34.6) 178 (31.0) 0.3835
   Housewife 29 (18.7) 73 (12.7) 86 (14.9)  
   Off sick 9 (6.0) 44 (7.6) 61 (10.6)  
   Unemployed 3 (1.8) 15 (2.6) 11 (1.9)  
   Retired 56 (35.5) 204 (35.3) 213 (37.0)  
   Unknown 8 (5.4) 41 (7.1) 26 (4.6)  
Elapsed time from diagnosis (years), mean (SD) 2.1 (3.1) 1.9 (3.4) 2.0 (3.4) 0.7130
Diagnosis (%)     
   Diabetic neuropathy 47.9 58.2 53.0 0.2852
   Post-herpetic neuralgia 37.2 31.2 36.9  
   Trigeminal neuralgia 14.9 10.7 10.1  
DN4 Questionnaire, mean (SD) 6.4 (1.7) 6.8 (1.8) 6.8 (1.7) 0.033
SF-MPQ, mean (SD)     
Total 18.5 (8.0) 21.0 (8.4) 21.1 (8.4) 0.002
PPI (0 - 5) 2.4 (0.9) 2.7 (0.8) 2.7 (0.9) <0.001
VAS (0 - 100) 66.8 (17.6) 71.4 (15.2) 72.6 (15.7) <0.001
Previous treatments#, n (%)     
   Mean (SD) 2.4 (1.3) 2.0 (1.1) 2.6 (1.4) <0.001
NSAID$ 66 (42.0) 140 (24.3) 311 (54.1) <0.001
Paracetamol 69 (43.7) 224 (38.8) 266 (46.3) 0.030
Metamizol 40 (25.7) 119 (20.7) 168 (29.2) 0.003
Opiates 70 (44.3) 153 (26.6) 244 (42.4) <0.001
AED 43 (27.5) 128 (22.2) 108 (18.8) 0.043
Tricyclic drugs 17 (10.8) 59 (10.2) 67 (11.7) 0.704
Others§ 12 (7.8) 35 (6.0) 79 (13.8) <0.001
  1. SD: Standard deviation; NSAID: non-steroidal anti-inflammatory drug; AED: antiepileptic drug; PGB: pregabalin; VAS: visual analogue scale; PPI: present pain intensity; SF-MPQ: Short Form McGill Pain Questionnaire; DN4: Doleur Neuropathique 4 questions scale. Total number of analyzed patients; some patients did not report all data; Between groups comparison; #Patients might be receiving more than one previous treatment; $Other than metamizol; §Includes vitamins, benzodiazepines, fosfosal, duloxetine.